EXELExelixisRunning, no new patients
Study of XL092 + Nivolumab vs Sunitinib in Subjects With Advanced or Metastatic Non-Clear Cell Renal Cell Carcinoma
Non-Clear Cell Renal Cell Carcinoma
2Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +1.5
3 insiders sold shares within a month
Since May 26, 2026 · was worth 10, fading over time
Worry score2
Score over time
- Stage
- Phase 3
- Patients
- 317 (final count)
- Started
- Jan 1, 2023
- Main results expected
- Dec 15, 2026
- Fully finished
- Jun 30, 2028
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Duration of Progression-free survival (PFS) per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1), by Blinded Independent Radiology Committee (BIRC)
Measured over: Approximately 27 months after the first subject is randomized
Objective response rate (ORR) as assessed by BIRC per RECIST 1.1
Measured over: Up to 24 months after the first subject is randomized
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- insider_selling_cluster: base 10, now 1.5, since 2026-05-26, fades (half-life)
Raw record changes
- none yet
Trial ID NCT05678673 · record last updated 2026-07-29 · checked 2026-11-09 15:47 UTC